Clinical Trials Directory

Trials / Unknown

UnknownNCT02103244

Validation of an Adjusted Dosing Algorithm of Carboplatin

Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function

Status
Unknown
Phase
Phase 4
Study type
Interventional
Enrollment
24 (estimated)
Sponsor
Rijnstate Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

An adjusted dosing algorithm for the dosing of the anticancer drug carboplatin has been developed, that accounts for high BMI, low serum creatinine values and maximal calculated renal function. The hypothesis is that this new dosing algorithm provides a more accurate and safe dose than dosing according to the old standard of care.

Detailed description

Carboplatin is an alkylating anticancer drug that is used for the treatment of various types of cancer, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), malignant mesothelioma, ovarian cancer, and breast cancer. It is mostly given in combination with other chemotherapeutic drugs, but it can also be given as single agent. Since carboplatin is highly eliminated by the kidneys, the dose needs to be adjusted for renal dysfunction. Furthermore, as there is clear correlation between the area under the concentration-time curve (AUC) of carboplatin and haematological toxicity and response rate, carboplatin is dosed per target AUC. For this, the standard pharmacokinetic formula \[dose = clearance carboplatin x target AUC\] is used. the clearance is typically calculated using the cockcroft and gault (C-G) formula. In patients with high weight, or very low serum creatinine values the C-G-formula may overestimate the renal function, resulting in a potential overdose of carboplatin. the new developed dosing algorithm to be studied adjusts for high BMI and low serum creatinine values, in order to provide a more safe dose of carboplatin

Conditions

Interventions

TypeNameDescription
DRUGCarboplatincarboplatin will be dosed according to newly developed dosing algorithm.

Timeline

Start date
2014-09-01
Primary completion
2015-09-01
Completion
2015-12-01
First posted
2014-04-03
Last updated
2014-04-03

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT02103244. Inclusion in this directory is not an endorsement.

Validation of an Adjusted Dosing Algorithm of Carboplatin (NCT02103244) · Clinical Trials Directory